

Speaker profiles

14th MMV Stakeholders' Meeting

11-12 October 2017, Bali, Indonesia |

Wednesday 11 October

Introductory Session

Dr David Reddy

CEO, Medicines for Malaria Venture (MMV)

Dr. David Reddy, PhD, is CEO of Medicines for Malaria Venture. This not-for-profit research foundation has brought forward seven new antimalarial drugs to malaria-endemic countries; and broadened its malaria drug pipeline to include ten novel compounds in clinical trials. MMV is guided by a Board and donor-approved 5-year strategy to develop and deliver new antimalarials to meet the needs of vulnerable populations. Over the last six years David and the MMV team have raised over \$450 million to support this strategy, whose ultimate goal is the elimination and eventual eradication of the disease.



David is a New Zealand / Swiss dual national, with 20 years of experience in the development and commercialization of medicines for the treatment of infectious diseases. His resume includes successful leadership of drug development teams, licensing and alliance management, market analytics and business planning, product and disease area management, and interfacing with Governments, NGOs and patient advocacy groups around access to medicines for priority diseases including HIV/AIDS and pandemic influenza. David has a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand.

Dr Siswanto

Head, National Institute of Health Research and Development (NIHRD), Indonesia

Dr Siswanto is currently Head of the National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia. His previous appointments were as Director, R&D Center of Applied Health Technology and Clinical Epidemiology as well as R&D Center Food and Nutrition, under the NIHRD. Prior to that, he was Head of the Division of Research Services, R&D Center of Policy and Health System, NIHRD.



Dr Siswanto graduated from the Faculty of Medicine, University of Airlangga in Indonesia in 1987. In 1998, he earned his Master of Health Planning from the University of New South Wales, Sydney, and in 2001, he received his Diploma of Tropical Medicine from Nagasaki University, Japan.

Dr Siswanto is also Chair of the National Authority for Containment (of GAP-III Polio Eradication) and Chair of the Expert Committee of Indonesian GHSA. Previously, he was assigned as National Committee on "Jamu Scientification".

Ms Joy Phumaphi

Executive Secretary, The African Leaders Malaria Alliance (ALMA)

Joy Phumaphi is the Executive Secretary of the African Leaders Malaria Alliance (ALMA). During her tenure, ALMA has grown to include 49 heads of state, pioneered innovative financing of malaria drugs and commodities and led the development and implementation of an accountability mechanism that regularly updates the Heads of State on progress towards the malaria goals.



Joy holds a B.Com. and a Masters in Financial Accounting and Decision Sciences. A Botswana national, she began public service in Botswana. From 1994 to 2003, she served in Parliament and as a representative to the Southern African Development Community. She entered the Cabinet with responsibility for lands and housing and developed the first national housing policy. Joy subsequently served as Minister for Health where she restructured the ministry to make it more focused on results while overseeing revision of the Public Health Act and putting into action a multi-sectoral plan to combat HIV/AIDS. She was Vice President and Head of the Human Development Network at the World Bank from 2007 until the end of 2009. Prior to this role, she was Assistant Director-General of the WHO.

Session 1: Malaria strategy post-2015—the quest for elimination

Dr Kesetebirhan Admasu

CEO, Roll Back Malaria (RBM)

Dr Kesete served as Minister of Health of the Federal Democratic Republic of Ethiopia from 2012 to 2016. Dr Kesete has dedicated his career to public service and scientific research focused on major public health problems in Ethiopia and has received numerous national and international awards.



A medical doctor by training with a master's degree in public health, Dr Kesete has served in a number of clinical and public health positions. He has worked as a public private partnership team leader, the CEO of a tertiary hospital and the Director General of health promotion and disease prevention before assuming his current position as CEO of the RBM Partnership To End Malaria.

Dr Peter Olumese

Medical Officer, World Health Organization (WHO)

Dr Olumese has been a Paediatrician and clinical pharmacologist for more than 24 years. Since 2001 he has held the position of Medical officer (Malaria treatment policies and case management) for the Global Malaria Programme Department at the WHO in Geneva. One of his main responsibilities is the WHO Guidelines for the Treatment of Malaria, now in its 3rd edition. Since 2009, Dr Olumese has been Co-chairman of the Roll Back Malaria Country and Regional Support Partners Committee (formally Harmonization Working Group).



Dr Rob van der Pluijm

Project Manager, Mahidol Oxford Research Unit (MORU)

Dr Rob van der Pluijm is a Dutch clinician-scientist who has been working at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok since 2014. Currently he coordinates the second phase of the Tracking Resistance to Artemisinin Collaboration (TRAC II) trial in 19 sites in 8 countries: Bangladesh, Cambodia, the Democratic Republic of Congo, India, Laos, Myanmar, Thailand and Vietnam.



TRAC II aims to map resistance to antimalarials and assess the tolerability, safety and efficacy of Triple Artemisinin based Combination Treatments (TACTs), which combine a standard Artemisinin based Combination Therapy (ACT) and a matching partner drug. The triple combinations will hopefully provide an effective treatment option in areas where ACTs are currently failing. Potentially TACTs could also prolong the longevity of the artemisinins and partner drugs in areas where ACTs still work.

Dr Ben Rolfe

CEO, Asia Pacific Leaders Malaria Alliance (APLMA)

Dr Ben Rolfe is the CEO of Asia Pacific Leaders Malaria Alliance secretariat, formerly hosted by the Asian Development Bank and now independently incorporated in Singapore. Ben was the former Lead Senior Specialist for the Pacific at the Australian Department of Foreign Affairs and Trade (DFAT) and has more than twenty years' experience in supporting health initiatives across 30 countries. Most recently at APLMA, he took a lead role in brokering the East Asia Summit agreement to eliminate malaria from the Asia Pacific by 2030.



Mr Alan Court

Senior Adviser, UN Secretary General's Special Envoy's Office

Alan Court is currently Senior Adviser to the United Nations' Secretary General's Special Envoy for Health in Agenda 2030 and for Malaria. Prior to this he had a long and distinguished career with UNICEF. Until 2008 he was the Director of the UNICEF Programme Division, where he oversaw UNICEF's program policy, guidance and management that assisted staff in the implementation of UNICEF programs and played a central role in guiding UNICEF programmes towards the achievement of the Millennium Development Goals.



Between 2000 and 2005, Mr Court served as Director of the UNICEF Supply Division in Copenhagen, where he was credited with turning the division's function into an innovative and cutting edge one that provided essential commodities and services to Governments through a mix of program and procurement services that directly impacted implementation as well as delivery performance, especially in Humanitarian Emergencies.

Before this Mr Court had a long and distinguished career in the field including postings as UNICEF Country Representative in India, Deputy Regional Director of the Americas and Caribbean region in Bogotá, Colombia, Representative in Bolivia, Special Representative in the former Yugoslavia and Representative in Chad. He also served in Nepal, Ethiopia, Indonesia and Bangladesh.

Prior to his UNICEF career Mr Court worked with Non-Governmental Organizations in Bangladesh and in Education in the United Kingdom. Mr Court holds a Master's Degree in Rural Social Development from the University of Reading School Of Education, UK.

Dr David Reddy

CEO, Medicines for Malaria Venture (MMV)

Dr. David Reddy, PhD, is CEO of Medicines for Malaria Venture. This not-for-profit research foundation has brought forward seven new antimalarial drugs to malaria-endemic countries; and broadened its malaria drug pipeline to include ten novel compounds in clinical trials. Please see page 2 for full bio.



Mr George Jagoe

Executive VP, Access and Product Management, Medicines for Malaria Venture (MMV)

As the EVP in charge of Access & Product Management, George leads MMV's team that focuses on increasing access to new medicines that we and our partners bring to market. Our work is built around strong alliances with pharma partners, malaria programmes, and implementing partners in-country. Prior to joining MMV, George was the first Country Director for the Clinton Foundation's HIV/AIDS Initiative in Mozambique, where CHAI's focus was supporting the scale-up of access to antiretroviral treatments via the national health system. He has also worked in the pharmaceutical industry (AstraZeneca Spain), integrated healthcare system management (Kaiser Permanente; Aetna International), and healthcare consulting (ChapterHouse). Before completing an MBA, he spent four years working with ACCION International to support the development of micro-enterprise programs throughout Latin America



Dr Tim Wells

Chief Scientific Officer, Medicines for Malaria Venture (MMV)

Dr Timothy Wells has been the Chief Scientific Officer of Medicines for Malaria Venture (MMV) since 2007, co-ordinating the development pipeline of new medicines from discovery through to post-approval studies. During his time at MMV he has led the implementation of collaborations based on high content screening, developments in translational medicine, and open access drug discovery. For the latter activity, MMV was given the Open Data Institute award from internet pioneer Tim Berners-Lee in 2015.



Prior to joining MMV, Tim had over 20 years' experience in drug discovery and development. From 1997 to 2006, he was the Head of Research for the Swiss biotech company Serono, developing products in neurology, immunology, oncology and reproductive health. Prior to this, he worked on inflammation and infectious disease for Glaxo, with a particular interest in cytokine biology and how it linked to protein structure.

In addition to his work at MMV, he advises on a variety of infectious disease projects, including tuberculosis and schistosomiasis. He is a non-executive director at Kymab, developing next generation monoclonal antibody technologies, and an interest to their applications in neglected disease. A long-time supporter of

the charity Reprieve, which fights for victims of human rights abuses, he was an expert adviser in 2016 on redrafting EU legislation to prevent medicines being exported for torture. He has 220 peer reviewed publications, and an H-index of 71, and in 2015 co-authored a book on drug design for neglected disease.

Tim received his PhD in Chemistry in 1987, on the engineering of enzyme transition states from Imperial College, London; his ScD in Biology in 2009, from Cambridge University in the UK, was mainly awarded for his work on cytokine biology. He is a fellow of the UK's Royal Society of Chemistry and of the Academy of Medical Sciences.

Mr Alan Court

Senior Adviser, UN Secretary General's Special Envoy's Office

Alan Court is currently Senior Adviser to the United Nations' Secretary General's Special Envoy for Health in Agenda 2030 and for Malaria. Please see page 4 for full bio.



Dr Elizabeth Winzeler

Professor, UC Health Sciences Center for Immunology, Infection and Inflammation, University of California, San Diego.

Elizabeth Ann Winzeler is a Professor at the University of California, San Diego, School of Medicine. She leads a group that uses systematic, data intensive methods to solve problems at the interface of host pathogen biology typically involving large collections of chemical screening data and whole genome sequencing at UC San Diego. She is a fellow of the American Academy in Microbiology. She has published more than 150 publications. She has received awards from the Keck Foundation, the Ellison Medical Foundation, and the Bill and Melinda Gates Foundation. In 2014 she was awarded the Bailey-Ashford Medal for distinguished achievements in tropical medicine, she received the 2017 Medicines of Malaria Venture Project of the Year, and was just awarded the 2018 Alice and C.C. Wang Award in Molecular Parasitology.



Dr Jetsumon Prachumsri

Director, Mahidol Vivax Research Unit

Dr Jetsumon received an MS in Microbiology and a PhD in Biology from Mahidol University in Bangkok, Thailand. She started her malaria research at AFRIMS in Bangkok, in 1985 before moving to Mahidol University in March of 2011 to establish the Malaria Center of Excellence at the Faculty of Tropical Medicine. Her research there has focused on malaria transmission and biology. She established a human cell line, HC04, which can support both *P. falciparum* and *P. vivax* liver-stage development. The cell line was patented in 2006. Her team of experienced researchers is one of a few groups that consistently works on the *P. vivax* parasite which cannot easily be cultured continuously *in vitro*. Her unique capacity to do research on *P. vivax* in collaboration with other research teams has contributed to the advancement of research on the parasite. She established the protocol to produce *P. vivax* infected *Anopheles dirus* from Thailand and transport them to the USA via courier. This capability enables US scientists and scientists from other countries to



evaluate new vaccine candidates and drugs against liver-stage *P. vivax*. She has published over 200 publications listed under **Sattabongkot J** and **Prachumsri J**. Her studies are being supported by US-DoD, US-NIH/NIAID, BMGF, MMV, and Korean NIH.

Prof Marcel Tanner

President, Swiss Academy of Sciences

Marcel Tanner obtained a PhD in Medical Biology from the University of Basel and a MPH from the University of London. He was Director of the Swiss Tropical and Public Health Institute from 1997 to 2015. Today, he is Professor of Epidemiology and Medical Parasitology at the University of Basel and at the Federal Institute of Technology. He is also President of the Swiss Academy of Sciences.



Since 1977, his research has ranged from basic research on the cell biology and immunology of malaria, schistosomiasis, trypanosomiasis and filariasis to epidemiological and public health research on risk assessment, vulnerability, health impact and district health planning. His research, teaching and health planning expertise are based on substantial long term experience from working in rural and urban areas in Africa (mainly Tanzania, Chad, Burkina Faso and Côte d'Ivoire) and Asia (China, Thailand, Laos). Capacity building and North-South partnerships were one of his main interests as reflected in the development of the Ifakara Health Institute in Tanzania. He has published extensively on many fields (>600 original papers). He also acts as an advisor on communicable diseases research and control, health systems strengthening and capacity building in various national and international agencies/bodies and on boards/committees such as e.g. WHO/STAC-TDR, Wellcome Trust, DNDi, NITD, INCLEN-Trust and INDEPTH.

Thursday 12 October

Session 2: Achieving impact by improving access to today's medicines

Dr Rini Poespoprodjo

Timika Research Facility, Indonesia

Dr Rukhsana Ahmed

Liverpool School of Tropical Medicine

Mr Won June Chang

CEO, Shin Poong

Ever since Mr WonJune Chang joined Shin Poong Pharmaceutical Co., Ltd. in 1999, he has been actively involved in the new ACT (PYRAMAX®) development project. From 2003 to 2009, he was an Executive Director of Shin Poong Pharmaceutical Co., Ltd,



handling not only PYRAMAX[®] development, but also overseas operations. In 2009, he became CEO of Shin Poong Pharmaceutical Co., Ltd. Mr Chang is a graduate of Harding University in the US and earned an MBA degree from Ajou University in Korea. Since 2002, Shin Poong Pharmaceutical Co., Ltd and MMV have worked in partnership to develop PYRAMAX[®], a high-quality, novel ACT and the commitment of this partnership has paid off with the positive scientific opinion under Article 58.

Ms Lily Su

Senior Vice President, Guilin Pharmaceutical Co., Ltd

Lily Su has eighteen years of professional experience in the pharmaceutical industry, specializing in international sales and marketing as well as business development.

Lily joined Fosun Pharma in 2007 as Head of International Business for Foun Pharma's antimalarial drugs manufactured by its subsidiary Guilin Pharma.



In the last ten years, Lily has helped seven antimalarial products of Guilin Pharma gain prequalification by the WHO and enter into the international procurement system as well as most malaria endemic countries of the world. She has also helped Guilin Pharma set up a sales network in sub-Saharan Africa covering 30 countries.

Dr Madan M Pradhan

State Programme Officer, National Vector Borne Diseases Control Programme, Odisha

Dr Madan Mohan Pradhan is a medical doctor with a master's degree in applied epidemiology. Currently, he is the State Programme Officer for the National Vector Borne Diseases Control Programme and Joint Director of Health Services in the Odisha state of India. He has been actively involved in public health activities since the beginning of his career. His assistance was key in setting up the multi-disease surveillance system as a response to the super-cyclone in 1999 in Odisha. He takes an active role in planning, training, implementing, monitoring and advocacy in the field of public health. He works in close collaboration with national, international and Non-Governmental organizations. He is involved in operational research activities with the Indian Council of Medical Research (ICMR). He is a key functionary in implementing the Comprehensive Case Management project in Odisha with the support of MMV and the National Institute of Malaria Research (NIMR) of ICMR. His concept of Malaria Elimination in the Inaccessible Areas (DAMaN) has been well acknowledged and is funded by the Odisha Government. He is part of the technical group for malaria elimination in India.




Dr Pradhan has led developmental projects related to health, education and social change in association with various state and national-level Non-Governmental Organizations. He also contributes to the Odia literature as a budding writer.

Session 3: New opportunities for expanding access to improved treatment for relapsing malaria.

Dr Ben Rolfe

CEO, Asia Pacific Leaders Malaria Alliance

Dr Ben Rolfe is the CEO of Asia Pacific Leaders Malaria Alliance secretariat, formerly hosted by the Asian Development Bank and now independently incorporated in Singapore. Please see page 4 for full bio.



Prof Kevin Baird

Eijkman-Oxford Clinical Research Unit (EOCRU)

Kevin Baird earned a B.Sc. in Microbiology and a M.Sc. in Biochemistry from University of Maryland in 1980 and 1983, and a Ph.D. in Medical Zoology from Tulane University School of Public Health and Tropical Medicine in 1994. He began working on primaquine and G6PD deficiency at the Division of Experimental Therapeutics at Walter Reed Army Institute of Research in 1981, and joined the US Navy Medical Service Corps in 1984. Over the next 22 years he served four tours of duty at US Naval Medical Research Unit #2 in Jakarta, Indonesia, along with assignments to Philippines, Ghana, Peru and Washington, DC. Since 2007 Kevin has directed the Eijkman-Oxford Clinical Research Unit in Jakarta on behalf of Oxford University, where he is Professor of Malariology in the Nuffield Department of Medicine. He is an expert on the prevention, control, treatment, and epidemiology of *Plasmodium vivax* malaria. He serves on several committees, working groups, and review groups at the World Health Organization's Global Malaria Programme. In 2005 the American Society of Tropical Medicine & Hygiene awarded him the Bailey K. Ashford Medal in recognition of distinguished work in the field of tropical medicine, and he became a Fellow of that Society in 2015.



Prof Ric Price

Menzies School of Health Research, Australia

Ric Price holds dual academic affiliation: Professor of Global Health at the Menzies School of Health Research in Darwin Australia and Professor of Tropical Medicine at the Centre of Tropical Medicine, University of Oxford, UK. He is a Wellcome Trust Senior Research Fellow in Clinical Medicine with a translational research program focused on improving the diagnosis and management of multidrug resistant *P. falciparum* and *P. vivax* infections. His work spans clinical drug trials, epidemiology, health economics, parasitology and molecular biology. Professor Price is head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN) and co-Chairs the Vivax Working Group of the Asia Pacific Malaria Elimination Network (APMEN).



Dr Leo Makita

Director, Vector Borne Disease Control Programmes, Papua New Guinea

Mr Leo Sora Makita is currently the director of the Vector Borne Disease Control Programs in Papua New Guinea (PNG).



Mr Makita graduated with a Bachelor of Science in Biology from the University of Papua New Guinea in 1980. He then became Junior Scientific Officer for the Malaria Control Program in PNG. In 1983 he went on to study entomology at the University of Georgia in Atlanta, USA. During this time he taught entomology part-time at the University of Georgia.

On his return to PNG he continued his work with the Malaria Control Program as a Scientific Officer in charge of one of the four regions. Several years later he became a parasitologist for the National Malaria Control Program.

In 1993 he began studying medical microbiology at the Institute of Medical Research. Upon his return to PNG, he was asked to establish the country's Central Public Health Laboratory (CPHL). Finding laboratory work a little boring, he again joined the Malaria Control Program as the Manager for the malaria surveillance and control unit of the program. In 1995 he was appointed the Principal Advisor for the Malaria Control Program in PNG. While running the Malaria Program, he began studying once again at the Institute of Medical Research in Kuala Lumpur for a diploma in parasitology and entomology. Upon completion he became the director of the Malaria Control Program in PNG.

In 1998 he enrolled at the Liverpool School of Tropical Medicine where he completed his Masters in Public health. Mr Makita has served as a consultant in Pakistan and Egypt as well as in numerous WHO meetings.

Dr Sariwati

Programme Manager, National Malaria Control Programme, Indonesia

Dr. Elvieda Sariwati, M.Epid is a National Malaria Control Program Manager, Ministry of Health, Indonesia since 2016.



She has a degree in medicine and a Master of Epidemiology from the University of Indonesia.

Over the years, she has worked in various positions and units, such as technical staff of the Epidemiological Surveillance and Outbreak Response Unit from 2002-2010, Deputy Program Manager of the National Malaria Control Program from 2010-2014 and National Acute Respiratory Infection Control Program Manager from 2014-2016.

Dr Marcus Lacerda

Physician, Doctor Heitor Vieira Dourado Foundation for Tropical Medicine

Marcus Lacerda received his medical degree from the University of Brasília (1999), completed an Infectious Diseases Residency at the Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT-HVD) (2002) and obtained his PhD in Tropical Medicine from the University of Brasília in partnership with New York University (2007). He works as a physician at FMT-HVD and as a researcher at Instituto Leônidas & Maria Deane (FIOCRUZ-Amazonas).



In addition, he collaborates with the Graduate Program on Tropical Medicine from the University of the Amazonas State, and is an Adjunct Professor at Kent State University. Since 2007 he has been the coordinator of the International Center for Clinical Malaria Research (CIPCLiM), in Manaus (Brazilian Amazon), and is currently the Director of Research at FMT-HVD. He is a member of the Technical Advisory Committee of the Brazilian National Malaria Control Program, the Committee on Antimalarial Therapy from the Brazilian Ministry of Health, and serves as an occasional consultant for the World Health Organization on *P. vivax* malaria. He is and has been actively involved in initiatives devoted to malaria elimination such as malERA, MESA and the Mesoamerica Initiative. He is also a member of the Expert Scientific Advisory Committee (ESAC) for Medicines for Malaria Venture (MMV) and WorldWide Antimalarial Resistance Network (WWARN). He is also an affiliate member of the Brazilian Academy of Sciences, and a level 1 researcher from CNPq.

Session 4: Next generation tools for blood stage infection

Dr Tim Wells

Chief Scientific Officer, Medicines for Malaria Venture (MMV)

Dr Timothy Wells has been the Chief Scientific Officer of Medicines for Malaria Venture (MMV) since 2007, coordinating the development pipeline of new medicines from discovery through to post-approval studies. Please see page 5 for full bio.



Dr David Hughes

Senior Global Program Head, Anti-infectives, Global Drug Development, Novartis Pharma AG

David is a Senior Global Program Head in clinical development based in Basel, Switzerland. He leads a number of cross-functional teams responsible for a broad portfolio of Anti-infective programs including antibacterial and antiviral agents, as well as compounds targeting Neglected Tropical Diseases including malaria. Previously he was a Senior Director in Novartis' Healthcare Systems Team, working with healthcare organizations around the world on partnership programs to improve patient outcomes and system productivity.



Previously, David was a Government Medical Officer and acting Hospital Superintendent at Chitungwiza General Hospital, in the Ministry of Health, Zimbabwe. He was also a Family & Emergency Medicine physician in Canada.


Prior to joining Novartis in February, 2011 he had extensive global pharmaceutical industry and business management experience during more than 10 years with Pfizer Inc. in New York & Hong Kong and 4 years with the management consulting firm McKinsey & Company in New York & London.

David is a board-certified physician (Canadian College of Family Physicians) with a Masters of Public Health in International Health from Johns Hopkins University

Dr Joe Camardo

Senior Vice President, Celgene Corporation

Doctor Camardo is Senior Vice President at Celgene Corporation. He earned an MD from the University of Pennsylvania School of Medicine in 1979 and completed residency training for Internal Medicine. Dr Camardo was a fellow in Neuroscience at Columbia University and at the University of Pennsylvania, where he worked on ion channels and behavior. In 1989 he joined the Clinical Research division of Wyeth-Ayerst Laboratories and ultimately became head of Clinical Research and Medical Affairs, at Wyeth. Dr Camardo is Chair of the Board of MaliHealth, an NGO that works with mothers and children in Bamako, Mali, a fellow at the College of Physicians of Philadelphia, a member of the Institute for Ethical Leadership and Social Responsibility at Rosemont College, and a board member of Anyone Can Fly, an arts foundation in NY.



Session 5: Next generation tools for relapsing malaria

Dr Marcus Lacerda

Director of Research, Doctor Heitor Vieira Dourado Foundation for Tropical Medicine

Marcus Lacerda has been the coordinator of the International Center for Clinical Malaria Research (CIPCLiM), in Manaus (Brazilian Amazon) since 2007, and is currently the Director of Research at FMT-HVD. Please see page 10 for full bio.



Prof Kevin Baird

Eijkman-Oxford Clinical Research Unit (EOCRU)

Since 2007 Kevin has directed the Eijkman-Oxford Clinical Research Unit in Jakarta on behalf of Oxford University, where he is Professor of Malariology in the Nuffield Department of Medicine. Please see page 9 for full bio.



Brice Campo

Director of Drug Discovery, Medicines for Malaria Venture (MMV)

Brice is Director of Drug Discovery at Medicines for Malaria Venture (MMV). There he leads drug discovery activities in the context of individual projects and pharmacology platforms. As Director of Drug Discovery, Brice provides scientific advice and leadership to a team working on an expanding portfolio of drug discovery activities as well as projects and pharmacology platforms. He works with partners from both academia and industry in order to deliver pertinent and optimal biological test cascades as well as safe and efficacious pre-clinical candidates which will be part of the next generation of antimalarials. Brice has a particular interest in molecules and biological assays that tackle the liver stage of the parasite and, more precisely, the hypnozoites reservoir



in order to find new drugs that will help eradicate malaria. He joined MMV in November 2011, bringing with him more than 14 years of experience in drug discovery, gained primarily through the Genomic Institute of the Novartis Foundation (GNF) and Addex Pharmaceuticals S.A. He has broad experience in molecular pharmacology and drug discovery in several disease areas such as neuroscience, metabolic disease and inflammation, and has successfully led and contributed to teams at all stages of drug discovery. Brice holds a PhD in Neuroscience and Immunology from the University of Sheffield (UK) and has published a significant number of scientific papers as well as patents.

Dr Elizabeth Winzeler

Professor

UC Health Sciences Center for Immunology, Infection and Inflammation, University of California, San Diego.

Elizabeth Ann Winzeler is a Professor at the University of California, San Diego, School of Medicine. She leads a group that uses systematic, data intensive methods to solve problems at the interface of host pathogen biology. Please see page 6 for full bio.



Dr Jetsumon Prachumsri

Director, Mahidol Vivax Research Unit

Dr Jetsumon started her malaria research at AFRIMS, Bangkok, Thailand, in 1985 before moving to Mahidol University in March 2011 to establish the Malaria Center of Excellence at the Faculty of Tropical Medicine. Please see page 6 for full bio.



Dr David Reddy

CEO, Medicines for Malaria Venture (MMV)

Dr. David Reddy, PhD, is CEO of Medicines for Malaria Venture. This not-for-profit research foundation has brought forward seven new antimalarial drugs to malaria-endemic countries; and broadened its malaria drug pipeline to include ten novel compounds in clinical trials. Please see page 2 for full bio.

